Our clinical research team is actively at the forefront of supporting potential effective therapy for the treatment of patients with COVID-19.

COVID-19 is an infectious disease caused by the most recently discovered coronavirus. This new virus and disease were unknown before the outbreak began in Wuhan, China (December 2019).

The SISCO Study is an observational case-control trial of siltuximab, a chimeric monoclonal antibody targeting human interleukin (IL)-6, for the treatment of patients infected with COVID-19 who develop serious respiratory complications.

The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo and supported by EUSA Pharma (EUSA). Ergomed is providing clinical research services for the study and has been integrally involved in the design and implementation of the study from a clinical and operational perspective.

In 10 days Ergomed Team provided a solution tailored to the unique requirement of the SISCO study.

“COVID-19 represents an unprecedented global healthcare challenge and the rapid evaluation of therapies which could alter the course of the infection and improve outcomes for patients is vital.

Ergomed is proud to be making a contribution to this effort by bringing our proven capabilities and expertise to bear on this important study.”

Dr Miroslav Reljanović
Ergomed PLC Executive Chairman

SISCO STUDY

Find out more about the SISCO Study

Learn more